Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Marginal Zone Lymphoma Pipeline Insight' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key Marginal Zone Lymphoma Companies, and future Marginal Zone Lymphoma treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report
Key Takeaways from the Marginal Zone Lymphoma Pipeline Report
In February 2025:- BeiGene:- The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
In February 2025:- Regeneron Pharmaceuticals:- This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).
In February 2025:- Oncternal Therapeutics Inc.:- This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.
In February 2025:- Genmab:- The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese patients with relapsed, progressive or refractory B-cell lymphoma and Japanese patients with B-cell lymphomas that have achieved partial response (PR) or complete response (CR).
In February 2025:- Janssen Research & Development LLC:- The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.
DelveInsight's Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Marginal Zone Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies
Marginal Zone Lymphoma Emerging Drugs
Tafasitamab: Incyte Corporation
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.
Amdizalisib (HMPL-689): HUTCHMED
The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3'-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin's lymphoma, including follicular lymphoma and marginal zone lymphoma.
Orelabrutinib: InnoCare Pharma
Orelabrutinib is a small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).
EO2463: Enterome
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.
The Marginal Zone Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.
Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs
Marginal Zone Lymphoma Companies
Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Marginal Zone Lymphoma Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Download DelveInsight's latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key Marginal Zone Lymphoma Developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Marginal Zone Lymphoma Pipeline Report
Coverage- Global
Marginal Zone Lymphoma Companies- Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight's exclusive Marginal Zone Lymphoma Pipeline Report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Marginal Zone Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Marginal Zone Lymphoma – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Tafasitamab: Incyte Corporation
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Orelabrutinib: InnoCare Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
EO2463: Enterome
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Marginal Zone Lymphoma Key Companies
Marginal Zone Lymphoma Key Products
Marginal Zone Lymphoma- Unmet Needs
Marginal Zone Lymphoma- Market Drivers and Barriers
Marginal Zone Lymphoma- Future Perspectives and Conclusion
Marginal Zone Lymphoma Analyst Views
Marginal Zone Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
8 hours ago
- Japan Forward
From First Female Sales Rep to Diversity Leader
このページを 日本語 で読む Japanese women are making a meaningful impact around the world. If they were ever invisible, certainly they are not now. What inspired them to step forward into their roles today? This time, JAPAN Forward set out to feature Midori Ito, who became the first female sales representative at Sekisui House, for our series " Groundbreakers ." Midori Ito served as a Standing Audit and Supervisory Board Member at Sekisui House, one of Japan's largest homebuilders. She retired from the company in the spring of 2025 after a long and successful career. Starting as the company's first female sales representative, over time, Ito took on a key role in promoting diversity. She supported female employees who wanted to continue working through various life stages. Even after retiring from the company, she hopes to create a society where people can live fulfilling lives. Her focus now extends beyond the corporate world. In 2018, shortly after being appointed an executive officer in charge of diversity at Sekisui House, Ito introduced a groundbreaking policy. It required male employees to take at least one full month of paternity leave. "I've always wanted to support motivated employees. Looking back, unfortunately, many women left their jobs because they had to shoulder housework, childcare, or eldercare alone," she recalls. "If partners support each other, they can both grow their careers. I believe that mandatory paternity leave could spark those vital conversations. And more than anything, it makes children happier too." The initiative drew widespread attention both inside and outside the industry. Midori Ito (©Sankei by Miyako Nagumo) Things were very different when Ito first joined Sekisui House. At the time, Japan had yet to enact the Equal Employment Opportunity Law. "When I first became a sales rep, most meetings were full of men. I definitely felt the pressure of being outnumbered," she recalls. But her uniqueness became her strength. "Being a woman made me stand out, and people remembered me," she says. Ito eventually became the company's first female sales representative. She later held roles such as store manager. Throughout her career, she sold a cumulative total of 300 homes and was even honored with the company's President's Award. "There was a time when I worried that customers wouldn't trust me just because I was a woman," she reflects. "But one customer once asked me, 'Why would being a woman be a problem?' It made me realize how meaningless it was to focus on gender differences. What really mattered was the value I offered the customer." When asked why she joined the company and the housing industry, she smiles. "It was a chance encounter — I just happened to see a newspaper ad. I didn't have a clear idea of what I wanted to do when I was young. And that was okay." Ito began her career as a sales assistant at a model home park in Sekisui House's Kobe Sales Office. From the start, she found fulfillment not only in satisfying customers but also in collaborating with her team. "The sense of joy and fulfillment in work comes from building it up, day by day," she reflects. Midori Ito (©Sankei by Miyako Nagumo) Unlike most women at the time, Ito continued working after marrying at 23. Back then, many female employees left the workforce upon marriage or childbirth. She credits her family's support for enabling her to keep going. "That's what people used to call 'marriage retirement,'" she explains. "When I got married, my husband respected my decision to keep working. After giving birth to my eldest daughter, I was transferred to a model home site near my house. But there was no formal maternity leave system at the time." Ito drew inspiration from her mother. "Back in the 1960s, she was financially independent and studied bookkeeping while working so she could move into a better profession," Ito recalls. "I'll never forget that when I confided in her about struggles at work in her later years, she smiled and said, 'Failure is the foundation of success.'" After returning to work, Ito became the company's first female general sales representative. At first, she accompanied her manager on sales visits. But when it came time to discuss contracts, customers often directed their questions to him. "I realized that if things continued like that, I'd never sell a house on my own," she says. "So I spoke up and asked to start handling sales independently." Her success came from genuine care for her clients. She visited company housing complexes and asked about residents' family structures and how long they'd lived there. Then she tailored proposals accordingly. She also distributed newsletters and housing information, gradually becoming a trusted advisor. "Day and night, I was always thinking about how to bring joy to the customers right in front of me," she recalls. "Even something as small as noticing, 'That household over there might be thinking of visiting a model home,' kept me motivated." Eventually, Ito was appointed store manager. "Two junior female employees approached me, saying they wanted to work in sales. When I brought it up with my manager, he agreed on the condition that I take responsibility and become the store manager. I couldn't say no after seeing the fire in their eyes," she explains. However, the new model home they were assigned to was built on the site of a former construction office. It was in a subdivision where most homes had already been sold. Some colleagues warned it was a bad idea. "I definitely sensed a 'Let's see what she can do' attitude," she says. "But it was an older subdivision, and many homes were aging. So we went door to door, reaching out to neighbors to tap into the demand for rebuilding. When we opened the model home, so many customers came that they couldn't all fit inside. We had to hold a pre-opening event to accommodate them." That initiative led to 17 years of continuous success in the area. Ito and her team maintained the top market share throughout. Her leadership was also evident during times of crisis — especially after the 1995 Great Hanshin Earthquake. At the time, she was the manager of the company's Yamanomachi model home site in Kobe. "As soon as I confirmed the safety of my family and employees, I rushed out to check on our homeowners," she says. "Not a single Sekisui House home was fully or partially destroyed. Seeing everyone's faces brought immense relief. It reaffirmed for me that a home is more than just a building — it's a shelter that protects lives and families." After turning 50, Ito reached a major turning point. Wanting to support the growth and retention of female sales staff across Japan, she volunteered to lead Sekisui House's newly established Women's Advancement Promotion Group. "The environments these women worked in and the challenges they faced were all different," she explains. "I kept asking myself, 'Are they truly receiving the support and development they need?' Until then, my focus had always been on helping customers directly. But I came to realize that by supporting female sales staff, I could indirectly support all of their customers, too." Her efforts soon expanded beyond gender, and Ito became a key driver of broader diversity initiatives. These included mandatory paternity leave for men and workplace accommodations for employees undergoing medical treatment. She worked to ensure Sekisui House could be a place where everyone could thrive, regardless of their circumstances. In the spring of 2025, Ito retired from Sekisui House after decades of dedicated service. She now continues her mission as a board member of the general incorporated association Expo 2025 Sakuyahime Congress — a group of female business leaders committed to improving lives. "It [the association] began with recipients of the first Osaka Sakuyahime Award, established in 2016 by the Osaka Chamber of Commerce and Industry to honor outstanding female leaders," Ito explains. "Led by Kayoko Fujimoto, CEO of the Fujimoto Yume Group, the group includes many influential women. We've formed deep bonds by openly sharing our challenges and how we've overcome them." The group was launched as a consortium in 2019 and became a general incorporated association in 2023. "We've been able to continue thanks to the support of so many people," Ito says. "I've always wanted to give back to my hometown, Osaka." At Expo 2025 Osaka, Kansai, the group is leading three key initiatives. One of them is the Sakuya Wolf Project, which features 10 wolf-shaped benches created by artist Tomoko Konoike. These benches are installed at the Osaka Healthcare Pavilion. Looking to the future, Ito says, "After the Expo, we plan to lend these benches to various locations free of charge. We want to use art to inspire and uplift communities." But Ito emphasizes that her focus goes beyond women to include broader diversity. "Ms Konoike reminded us that even the term 'women's empowerment' can sometimes create divisions," she explains. "Our goal is to support everyone, not just women. Through connection, we hope to help build a future rooted in well-being at its core." Founded in 1960, Sekisui House is one of Japan's leading homebuilders. In recent years, the company has expanded its global presence, particularly in the United States, with a focus on detached housing. For the fiscal year ending January 2025, Sekisui House reported sales of ¥4.0585 trillion JPY (around $27.9 billion USD). As of January 2025, the company employed 15,664 people on a standalone basis, including 3,320 licensed first-class architects. ( Read the interview in Japanese . ) Interview by: Naomi Yasuda, The Sankei Shimbun このページを 日本語 で読む
Japan Forward
12 hours ago
- Japan Forward
SUZUMO Takes Japan's Delicious Rice Culture Global with Cutting-edge Tech
このページを 日本語 で読む Sushi, onigiri, and donburi are emblematic of Japanese cuisine everywhere they're found. At the heart of their culinary global reach is Suzumo Machinery Co, Ltd, the pioneer in rice processing machinery. Its innovations have helped deliver the "deliciousness and warmth" of Japanese rice to the world, fueling an international boom in Japanese food. In April, SUZUMO ushered in a new era of leadership. Minako Suzuki, a member of the founding family and the company's former president, is now Chairman. At the same time, Vice President and Chief Operating Officer Toru Taniguchi is the new President. Determined to share the company's future vision and evolving missions, the two executives sat down for an exclusive interview with JAPAN Forward at SUZUMO's headquarters in Tokyo. "Our rice processing machines deliver real value to customers by improving efficiency, reducing labor, and ensuring uniformity in the foods made by the machines," says Taniguchi. The newly appointed president emphasizes that SUZUMO's strength lies in its commitment to "spreading the word about delicious food," a mission that has guided the company since its inception. "We're not just selling machines, we're carrying forward our founder's vision of delivering Japan's culinary culture to the world." President Toru Taniguchi (©Hidemitsu Kaito) "Our goal is to create something that doesn't yet exist," Chairman Suzuki explains. She learned this lesson directly from her father, the company's founder. "Inheriting the founder's philosophy, our corporate vision is 'Delivering "Deliciousness" and "Warmth" to the world' through our machines," she adds. SUZUMO Chairman Minako Suzuki. (©Hidemitsu Kaito） Nevertheless, the journey toward realizing this vision has been far from easy. Over half a century ago, the founder made a bold decision to focus on machinery for processed rice products instead of confectionery equipment. That strategic shift laid the foundation for the company's success today. "We entered the United States market in the 1980s and experienced the sushi boom firsthand," Taniguchi recounts. "At the time, sushi often looked appealing but lacked authentic taste. That's when we realized the importance of offering guidance on rice preparation and other fundamentals." "Japanese food overseas can become even more delicious. And we provide value-added services to make that possible," he adds. "That is our strength." SUZUMO is highly regarded for its comprehensive after-sales care, which starts even before machine installation and extends through years of use, including maintenance and repair services. SUZUMO's compact Sushi Machine efficiently shapes sushi, which can be automatically transferred to trays using the Sushi Transfer Unit. In Japan, sushi restaurants, supermarkets, diners, hotels, takeout and delivery specialty stores, and food processing factories are all expanding their use of rice processing machines for various purposes. This widespread acceptance is helping to expand SUZUMO's business, with overseas demand growing especially rapidly. According to a survey by the Ministry of Agriculture, Forestry and Fisheries, the number of Japanese restaurants overseas has surged to approximately 187,000 in 2023, compared to around 55,000 in 2013. It's a remarkable 3.4-fold increase in just ten years. SUZUMO's products are now available in over 90 countries worldwide. In recent years, overseas sales have grown from around 20% to nearly 30% of total revenue. North America leads these with 44.5% of overseas sales, while Asia and Europe also continue to be strong markets. The Middle East is likewise emerging as a promising region. There, demand is driven by rising sushi demand in countries such as the United Arab Emirates, with its affluent consumers. At international exhibitions, live demonstrations of making sushi and rice balls draw significant interest from attendees. (Scene from the NRA Show in the United States.) "With widespread access to information through social media, interest in Japanese cuisine is naturally spreading worldwide, beginning with overseas travelers," Taniguchi explains. "Pairing rice with various other ingredients is virtually limitless, and rice-based dishes will only continue to multiply." He explains that the company is actively adapting its offerings to suit local tastes. "Dishes like chicken katsu curry and poke-don (Hawaiian-style tuna bowls) are becoming popular in Europe. As long as rice-based meals keep spreading, there will always be a role for us." Even university cafeterias in the United States are now using SUZUMO's Rice-Serving Machine Fuwarica. "As Japanese food gains in popularity, different communities are developing their own local ways of preparing and enjoying Japanese cuisine," Suzuki adds. It is no exaggeration to say that Japanese food is evolving beyond its traditional roots, giving rise to entirely new, rice-based culinary cultures. "Adapting to local food cultures is essential," Suzuki emphasizes, suggesting that growth lies in embracing change itself. In America, sushi is widely available in supermarkets and other retail stores as well as restaurants. (The sushi section at a US supermarket.) While the domestic sushi restaurant market is reaching maturity, SUZUMO is looking forward. The company is actively promoting the adoption of its Rice-Serving Machine Fuwarica across the full spectrum of establishments, including small restaurants. Fuwarica features a proprietary "rice loosening function," which, as Suzuki explains, "adds just the right amount of air to freshly cooked rice to create a fluffy texture." It's a product born from the continuous pursuit of truly delicious rice. For SUZUMO, innovation in rice technology never stops. Rice-Serving Machine Fuwarica is equipped with intuitive touch controls and dispenses warm, fluffy rice in precise portions with excellent hygiene. It's now in use at airport lounges and other high-traffic locations. The ONIGIRI WOW! shop at Expo 2025 Osaka, Kansai. (Photo courtesy of Zojirushi Corporation via SUZUMO) SUZUMO's Fluffy Onigiri molding machine is helping Zojirushi to serve perfectly shaped rice balls at the Expo's ONIGIRI WOW! shop. (Photo courtesy of Zojirushi Corporation via SUZUMO) At the ongoing Expo 2025 Osaka, Kansai, Zojirushi Corporation is hosting an onigiri specialty shop called "ONIGIRI WOW!" It offers visitors a chance to experience the fluffy texture of perfectly prepared rice. SUZUMO has provided the shop with its Fluffy Onigiri moulding machine, enabling guests to enjoy freshly made, delicious rice balls with ease. "Our machines are being used at the Expo to prepare sushi and rice bowls," explains Taniguchi, who visited the venue. "It's a wonderful opportunity for people around the world to experience Japanese food culture, from sushi and onigiri to donburi. "I'm thrilled to see the Expo helping to champion the appeal of Japanese cuisine," he adds. To meet the growing demand for its latest products, the company is currently building a new factory in Saitama Prefecture. "We plan to introduce more efficient production methods and expand our manufacturing capacity," Suzuki notes. The facility is scheduled to begin operations in March 2026. Rendering of SUZUMO's new factory under construction in Tsurugashima City, Saitama Prefecture. (Courtesy of Suzumo Co, Ltd.) SUZUMO is also prioritizing digital services and AI-driven solutions to enhance not only kitchen workflow, but also overall restaurant operations. Looking ahead, the company aims to accelerate the development of versatile, value-added services, including potential partnerships with outside firms. "As a food lifestyle producer, we aim to enhance SUZUMO's social value and solidify our business foundation," Taniguchi says, bringing the interview to a close. "Our goal is to achieve sustainable growth through management that balances profitability with a commitment to the SDGs and sound governance." This article is published in cooperation with Suzumo Machinery Co Ltd . Author: JAPAN Forward このページを 日本語 で読む
Japan Forward
14 hours ago
- Japan Forward
Immigration in Japan: So, You Want to Live Here?
このページを 日本語 で読む In Chitose, Hokkaido, Taki Kensetsu Kogyo is quietly reshaping what immigration can look like in Japan. Led by Yuichi Taki, the small construction firm employs workers from over ten countries and supports them with multilingual manuals and a practical, empathetic work culture. Taki believes that if Japan needs foreign labor, it must also create an environment where people can thrive. His company shows what's possible when both sides commit. Yet such examples remain rare. As Japan struggles to attract and retain foreign residents, the question remains: what's holding it back? This is exactly the question author and expert Fusako Yanase explores in part five of her series on immigration. In this installment, she examines the practical and social barriers facing immigrants in Japan, from language and licensing to education and long-term integration. Fifth in the series. Read the series Immigration in Japan Language remains one of the most significant barriers. In Japan, it's nearly impossible to find employment without Japanese proficiency, and most certification exams require it as well. Yet even after investing time and effort into learning the language, its utility beyond Japan can be minimal. A foreign friend of mine once joked, "I married a Japanese partner and learned the language to live with their family, but outside Japan, it's useless. Talk about a poor return on investment!" For someone who works entirely in English, it's natural to want to get started quickly using English rather than learn a local language from scratch. And even for non-native English speakers, if they're already used to the alphabet, countries that use it may feel more accessible and easier to adapt to. Is this barrier inevitable just because Japanese is the dominant language? Aspiring for jobs in Japan, Vietnamese students learn Japanese ( © Sankei) Not necessarily. Language barriers exist all over the world, but creative solutions can lower them. There are two main ways to lower Japan's language barrier: Increase support for Japanese language education for incoming foreigners and their families. Expand the number of workplaces in Japan where people can work in English (or other languages). Japan lacks both options. That is why it remains a less attractive destination for foreign workers. This isn't unique to Japan, but whether someone can utilize their career or qualifications from their home country can be a critical factor. Even those with advanced professional expertise often find that Japan is not a country where it's easy to qualify for their prior careers. For example, someone who is a doctor or nurse in their home country must pass Japan's national medical or nursing exam to practice. This is a common international challenge. However, a few countries have mutual recognition agreements for medical qualifications. Japan, though, has very few such agreements. Even experienced teachers with years in the classroom must obtain a Japanese teaching license to work in schools. Former business owners face similar hurdles. Without proficiency in reading, writing, and speaking Japanese, starting a business or securing financing can be a major challenge. Skilled professionals in fields like beauty or hairstyling also run into obstacles, as many national certification exams are conducted entirely in Japanese. For those who have fled their homeland to Japan, finding employment and achieving financial independence is an immediate priority. And for those planning to stay even temporarily, ensuring a supportive educational environment for their children becomes equally important. Japan provides free compulsory education. Children of refugee applicants working under a "Designated Activities – Work Permitted" visa are eligible to attend public kindergartens, nurseries, and elementary or junior high schools. In many cases, even those without legal status can enroll their children by applying directly to the educational institution. These services are funded by Japanese taxpayers. However, it's important to remember that foreign residents also contribute through taxes once they begin working. In recent years, despite problems in some areas, the idea of multicultural coexistence has gained broader acceptance. It has become increasingly rare for Japanese parents or students to view Japanese language instruction or supplemental support for foreign children as discriminatory. Many, in fact, now actively support and cooperate with these efforts. Foreign technical intern trainees have been working in caregiving in Japan. Hikone, Shiga Prefecture (©Sankei by Sarasa Shimizu) In urban daycare centers and schools, it is now entirely normal to see children from diverse backgrounds learning in Japanese, side by side with their Japanese peers. When people claim that "Japan accepts very few refugees," the focus is often limited to the small number of applicants who meet the officially recognized definition of refugee. This narrow view fuels the perception that "Japan rejects foreigners." And from there, the debate quickly turns to calls for reforming the immigration and refugee recognition system. While legal reforms are certainly worth discussing, a broader perspective reveals a deeper issue: Japan is increasingly not being chosen as a destination by refugees or by other would-be immigrants. Asking "Why isn't Japan being chosen?" prompts a closer look at the structural and social challenges that make life in Japan difficult for non-Japanese residents and those with foreign roots. What aspects of Japanese society are unwelcoming or inconvenient? What makes long-term settlement so difficult? Addressing these questions is essential — not only for supporting those who genuinely need protection, but also for helping Japan evolve into a more inclusive and multicultural society. A December 2, 2023, feature in Weekly Toyo Keizai titled "Foreign Workers Aren't Coming! Companies That Get Chosen, Companies That Are Abandoned" made the point starkly. Japan is no longer a "chosen country," and the day may soon come when foreign workers stop coming altogether. The next installment dives into this very topic. Japan was once a top destination for workers from emerging Asian nations, known for offering strong earning potential. But as of December 2023, South Korea had taken the lead, with Japan in second place and Taiwan rapidly closing in. Saddled with a weakened yen, Japan no longer held the same appeal it once did. Foreign residents serve as a mirror reflecting the strengths and weaknesses of Japanese society. Many of the challenges they face, whether in language education, skills training, or access to housing that accommodates religious and cultural needs, require more than policy tweaks. Real progress depends on sufficient government investment and broad support from the private sector. These are not issues that immigration reform alone can fix. So, how do you see it? Continues in Part Six: What Brings Refugees to a New Land? Author: Fusako Yanase In addition to being an expert on immigration, Yanase is a best-selling author and former Honorary Chair of the Certified NPO Association for Aid and Relief, Japan. このページを 日本語 で読む
